Navigation Links
Aurigene to Present its CDK7, Dual PD-1/VISTA and IRAK4 Inhibitor Programs at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (November 5-9, Boston, MA)

BOSTON, November 3, 2015 /PRNewswire/ --

Aurigene will present data on its potent and selective CDK7 novel covalent inhibitor program, which is currently in Lead Optimization.


Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the AACR-NCI-EORTC International Conference.

Aurigene and Curis will present data on:

(A) First-in-class orally available PD-L1/VISTA antagonists for cancer therapy

(B) interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor  

Additional information on the presentations can be found below and abstracts can be accessed at  

Poster Presentations  

First-in-class orally available immune checkpoint antagonists: PD-L1/VISTA  

Title: First-in-class orally available immune checkpoint antagonists for cancer therapy  

Session ID:               Poster Session A

Session Title:            Immune Modulators

Session Date and Time:     Friday Nov 6, 2015 12:15 PM - 3:15 PM

Location:                 Exhibit Hall C-D

Permanent Abstract Number: A96

Selective CDK7 Covalent Inhibitors  

Title: Potent and selective inhibition of CDK7 by novel covalent inhibitors Session Category: Experimental and Molecular Therapeutics  

Session ID:                Poster Session C

Session Title:             Therapeutic Agents: Small Molecule Kinase Inhibitors

Session Date and Time:     Sunday Nov 8, 2015 12:30 PM - 3:30 PM

Location:                  Exhibit Hall C-D

Permanent Abstract Number: C190

Novel, selective IRAK4 Inhibitors for Oncology  

Title: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models   

Session ID:                Poster Session C

Session Title:             Therapeutic Agents: Small Molecule Kinase Inhibitors

Session Date and Time:     Sunday Nov 8, 2015 12:30 PM - 3:30 PM

Location:                 Exhibit Hall C-D

Permanent Abstract Number: C191

About Aurigene:  

Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene's Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has signed four licensing deals in the last couple of years. Aurigene is currently seeking partners for its current pipeline of advanced assets (a) RORg for autoimmune diseases which is in preclinical development (b) Novel NAMPT inhibitors for niche cancers, also in preclinical development (c) Covalent CDK7 and KRAS small molecule programs that are currently in lead optimization. For more information about Aurigene and our pipeline, please visit Aurigene's website at

Media Contact:
Rajshree KT
Director Corporate Development & Strategy
+91-40-4465 7777 

SOURCE Aurigene Discovery
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. SciClone To Present At Boston Biotech NY/NJ CEO Conference On November 12th
2. AbbVie to Present at Credit Suisse 24th Annual Healthcare Conference
3. Data Supporting Delcaths CHEMOSAT System Presented At The European Association Of Dermato Oncology Annual Congress
4. Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
5. Douglas C. Wu, M.D., Ph.D., Presents The New Picoway Laser At The Aesthetics Academy
6. Perrigo Comments On Mylans Presentation
7. Warner Chilcott to Pay $125 Million to Resolve Kickback Allegations; Seeger Weiss LLP Represented Relators in Historic Healthcare Fraud Whistleblower Lawsuit
8. AMRI to Present at Credit Suisse Healthcare Conference
9. Ardelyx Announces Upcoming Presentations for Tenapanor at the American Society of Nephrologys Kidney Week Meeting 2015
10. 2015 Coagulation Testing Market - Presents Analyses of Major Manufacturers of Coagulation Products in Terms of their Sales, Market Shares and Product Portfolios
11. Henry Schein to Present at Two Investor Conferences in November
Post Your Comments:
(Date:6/24/2020)... ... June 24, 2020 , ... People curious about chiropractic medicine ... County Line Chiropractic’s YouTube channel. Dr. Vivian Solivan, one of County Line ... locations in the South Florida area, including the Lauderhill office, where Dr. Solivan ...
(Date:6/23/2020)... ... 23, 2020 , ... Draper today announced the release of ... to test an in vitro human lung model to investigate responses following infection ... Draper and the University of Massachusetts Medical School . The manuscript, ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... May 11, 2020 which now features a greatly enlarged and enhanced medical facility. ... below-grade basement structures, water tanks, and rooftop garden. , Part of the Bangkok ...
Breaking Medicine Technology:
(Date:7/1/2020)... ... July 01, 2020 , ... ... clinical development of psychedelics and analogues, announces its core executive team. The co-founders ... product drug discovery, novel formulations, and as distinguished researchers within the cannabis industry. ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... it has been selected by Codiak BioSciences to support its cleanroom build out ... the cleanroom infrastructure for the drug substance and product manufacturing for its clinical ...
(Date:6/28/2020)... (PRWEB) , ... June 26, 2020 , ... ... whose mission is to provide high-quality, intensive education and training that prepares graduates ... Joyce Williams as new member of the Board of Trustees. , Ms. Williams ...
(Date:6/28/2020)... Calif. (PRWEB) , ... June 26, 2020 , ... ... tougher. Inland Detox, the Inland Empire’s premier residential addiction treatment center, proudly announces ... services that now includes special preparation for recovery in a world affected by ...
(Date:6/28/2020)... ... 27, 2020 , ... The secret of surviving a pandemic with one’s sanity ... paper. Yet, it was the first product to disappear off the shelves when the ... have stockpiled, the less need to venture out, the longer you can “survive”. However, ...
Breaking Medicine News(10 mins):